Evidence map›Paper›PMID 27621575›Full record

ReviewWorld journal of gastroenterology2016

Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Stephen L Chan, Charing C N Chong, Anthony W H Chan, Darren M C Poon, Kenneth S H Chok

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03452553 (A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma), which is not on this map. Cited by 108 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03452553 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin

TypeinterventionalSponsorBoston Scientific CorporationRan2018 to 2020Enrolled0ConditionsHepatocellular Carcinoma (HCC)ArmsLC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Stephen L ChanStephen L Chan, State Key Laboratory in Oncology of South China, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Charing C N ChongStephen L Chan, State Key Laboratory in Oncology of South China, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Anthony W H ChanStephen L Chan, State Key Laboratory in Oncology of South China, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Darren M C PoonStephen L Chan, State Key Laboratory in Oncology of South China, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Kenneth S H ChokStephen L Chan, State Key Laboratory in Oncology of South China, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
Creative Research Enterprises (United States) · USQueen Mary Hospital · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Portal vein tumor thrombosis (PVTT) is a common phenomenon in hepatocellular carcinoma (HCC). Compared to HCC without PVTT, HCC with PVTT is characterized by an aggressive disease course, worse hepatic function, a higher chance of complications related to portal hypertension and poorer tolerance to treatment. Conventionally, HCC with PVTT is grouped together with metastatic HCC during the planning of its management, and most patients are offered palliative treatment with sorafenib or other systemic agents. As a result, most data on the management of HCC with PVTT comes from subgroup analyses or retrospective series. In the past few years, there have been several updates on management of HCC with PVTT. First, it is evident that HCC with PVTT consists of heterogeneous subgroups with different prognoses. Different classifications have been proposed to stage the degree of portal vein invasion/thrombosis, suggesting that different treatment modalities may be individualized to patients with different risks. Second, more studies indicate that more aggressive treatment, including surgical resection or locoregional treatment, may benefit select HCC patients with PVTT. In this review, we aim to discuss the recent conceptual changes and summarize the data on the management of HCC with PVTT.

Indexed as

Portal VeinCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyHumansLiver NeoplasmsStentsThrombectomyVenous ThrombosisLiver cancerRadiotherapySurgeryTargeted agentVascular invasion

Identifiers

PMID27621575
PMCPMC4997643
OpenAlexW2507237883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.